biomarker_id	biomarker	assessed_biomarker_entity	assessed_biomarker_entity_id	assessed_entity_type	condition	condition_id	exposure_agent	exposure_agent_id	best_biomarker_role	specimen	specimen_id	loinc_code	evidence_source	evidence	tag
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:3063529	Each of the patients has excreted large amounts of 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid in the urine;|The pattern of organic aciduria associated with HMG-CoA lyase deficiency is characteristic. It includes increased urinary excretion of 3-hydroxyisovaleric, 3-methylglutaric, 3-methylglutaconic and 3-hydroxy-3-methylglutaric acids.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6085636	3-Hydroxy-3-methylglutaric acidura has been reported in 10  patients. This disorder is caused by a deficiency in activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, and elevated amounts of 3-methylglutaric acid and 3-hydroxyisovaleric acid.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:1000872	The urinary organic acid profile of 3-hydroxy-3-methylglutaric aciduria contains excessive amounts of 3-methylglutaconic acid, 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid and 3-methylglutaric acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6489380	Urinary organic acid analysis, performed as described below, revealed metabolites suggestive of 3-hydroxy-3-methylglutaric aciduria.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:32685354	The diagnosis is currently made by measuring dry blood spot acylcarnitines (C5OH and C6DC) followed by urinary organic acid profiling for the differential diagnosis from several other disorders.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15505778	Urine excretion of 3-hydroxy-isovaleric acid, 3-methyl-glutaric acid, 3-methyl-glutaconic acid, and 3-hydroxy-3-methylglutaric acid were increased as determined by gas chromatography mass spectrometry (see Table). These metabolites were considered diagnostic of HMG CoA lyase deficiency.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:17692550	A preliminary diagnosis of HL deficiency may be indicated by the characteristic urinary organic acid profile, which includes high levels of 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-3-methylglutaric acid	3-hydroxy-3-methylglutaric acid	PCCID:1662	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15164951	A preliminary diagnosis can be obtained from the characteristic urinary organic acid profiles, which include 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:17692550	A preliminary diagnosis of HL deficiency may be indicated by the characteristic urinary organic acid profile, which includes high levels of 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6085636	3-Hydroxy-3-methylglutaric acidura has been reported in 10  patients. This disorder is caused by a deficiency in activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, and elevated amounts of 3-methylglutaric acid and 3-hydroxyisovaleric acid.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15505778	Urine excretion of 3-hydroxy-isovaleric acid, 3-methyl-glutaric acid, 3-methyl-glutaconic acid, and 3-hydroxy-3-methylglutaric acid were increased as determined by gas chromatography mass spectrometry (see Table). These metabolites were considered diagnostic of HMG CoA lyase deficiency.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15164951	A preliminary diagnosis can be obtained from the characteristic urinary organic acid profiles, which include 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:32685354	The diagnosis is currently made by measuring dry blood spot acylcarnitines (C5OH and C6DC) followed by urinary organic acid profiling for the differential diagnosis from several other disorders.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:1000872	The urinary organic acid profile of 3-hydroxy-3-methylglutaric aciduria contains excessive amounts of 3-methylglutaconic acid, 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:3063529	Each of the patients has excreted large amounts of 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid in the urine;|The pattern of organic aciduria associated with HMG-CoA lyase deficiency is characteristic. It includes increased urinary excretion of 3-hydroxyisovaleric, 3-methylglutaric, 3-methylglutaconic and 3-hydroxy-3-methylglutaric acids.	best_biomarker_role;condition
AN6165-1	Increased 3-hydroxy-isovaleric acid	3-hydroxy-isovaleric acid	PCCID:69362	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6489380	Urinary organic acid analysis, performed as described below, revealed metabolites suggestive of 3-hydroxy-3-methylglutaric aciduria.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:3063529	Each of the patients has excreted large amounts of 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid in the urine;|The pattern of organic aciduria associated with HMG-CoA lyase deficiency is characteristic. It includes increased urinary excretion of 3-hydroxyisovaleric, 3-methylglutaric, 3-methylglutaconic and 3-hydroxy-3-methylglutaric acids.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6085636	3-Hydroxy-3-methylglutaric acidura has been reported in 10  patients. This disorder is caused by a deficiency in activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, and elevated amounts of 3-methylglutaric acid and 3-hydroxyisovaleric acid.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15505778	Urine excretion of 3-hydroxy-isovaleric acid, 3-methyl-glutaric acid, 3-methyl-glutaconic acid, and 3-hydroxy-3-methylglutaric acid were increased as determined by gas chromatography mass spectrometry (see Table). These metabolites were considered diagnostic of HMG CoA lyase deficiency.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15164951	A preliminary diagnosis can be obtained from the characteristic urinary organic acid profiles, which include 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:32685354	The diagnosis is currently made by measuring dry blood spot acylcarnitines (C5OH and C6DC) followed by urinary organic acid profiling for the differential diagnosis from several other disorders.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:1000872	The urinary organic acid profile of 3-hydroxy-3-methylglutaric aciduria contains excessive amounts of 3-methylglutaconic acid, 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:17692550	A preliminary diagnosis of HL deficiency may be indicated by the characteristic urinary organic acid profile, which includes high levels of 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaconic acid	3-methylglutaconic acid	PCCID:1551553	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6489380	Urinary organic acid analysis, performed as described below, revealed metabolites suggestive of 3-hydroxy-3-methylglutaric aciduria.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6085636	3-Hydroxy-3-methylglutaric acidura has been reported in 10  patients. This disorder is caused by a deficiency in activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, and elevated amounts of 3-methylglutaric acid and 3-hydroxyisovaleric acid.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:17692550	A preliminary diagnosis of HL deficiency may be indicated by the characteristic urinary organic acid profile, which includes high levels of 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15164951	A preliminary diagnosis can be obtained from the characteristic urinary organic acid profiles, which include 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:15505778	Urine excretion of 3-hydroxy-isovaleric acid, 3-methyl-glutaric acid, 3-methyl-glutaconic acid, and 3-hydroxy-3-methylglutaric acid were increased as determined by gas chromatography mass spectrometry (see Table). These metabolites were considered diagnostic of HMG CoA lyase deficiency.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:32685354	The diagnosis is currently made by measuring dry blood spot acylcarnitines (C5OH and C6DC) followed by urinary organic acid profiling for the differential diagnosis from several other disorders.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:1000872	The urinary organic acid profile of 3-hydroxy-3-methylglutaric aciduria contains excessive amounts of 3-methylglutaconic acid, 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:3063529	Each of the patients has excreted large amounts of 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid in the urine;|The pattern of organic aciduria associated with HMG-CoA lyase deficiency is characteristic. It includes increased urinary excretion of 3-hydroxyisovaleric, 3-methylglutaric, 3-methylglutaconic and 3-hydroxy-3-methylglutaric acids.	best_biomarker_role;condition
AN6165-1	Increased 3-methylglutaric acid	3-methylglutaric acid	PCCID:12284	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	urine	UBERON:0001088		Pubmed:6489380	Urinary organic acid analysis, performed as described below, revealed metabolites suggestive of 3-hydroxy-3-methylglutaric aciduria.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:32685354	The diagnosis is currently made by measuring dry blood spot acylcarnitines (C5OH and C6DC) followed by urinary organic acid profiling for the differential diagnosis from several other disorders.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:1000872	The urinary organic acid profile of 3-hydroxy-3-methylglutaric aciduria contains excessive amounts of 3-methylglutaconic acid, 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:6085636	3-Hydroxy-3-methylglutaric acidura has been reported in 10  patients. This disorder is caused by a deficiency in activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, and elevated amounts of 3-methylglutaric acid and 3-hydroxyisovaleric acid.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:15505778	Urine excretion of 3-hydroxy-isovaleric acid, 3-methyl-glutaric acid, 3-methyl-glutaconic acid, and 3-hydroxy-3-methylglutaric acid were increased as determined by gas chromatography mass spectrometry (see Table). These metabolites were considered diagnostic of HMG CoA lyase deficiency.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:3063529	Each of the patients has excreted large amounts of 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid in the urine;|The pattern of organic aciduria associated with HMG-CoA lyase deficiency is characteristic. It includes increased urinary excretion of 3-hydroxyisovaleric, 3-methylglutaric, 3-methylglutaconic and 3-hydroxy-3-methylglutaric acids.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:17692550	A preliminary diagnosis of HL deficiency may be indicated by the characteristic urinary organic acid profile, which includes high levels of 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:15164951	A preliminary diagnosis can be obtained from the characteristic urinary organic acid profiles, which include 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:6489380	Urinary organic acid analysis, performed as described below, revealed metabolites suggestive of 3-hydroxy-3-methylglutaric aciduria.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:32685354	The diagnosis is currently made by measuring dry blood spot acylcarnitines (C5OH and C6DC) followed by urinary organic acid profiling for the differential diagnosis from several other disorders.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:1000872	The urinary organic acid profile of 3-hydroxy-3-methylglutaric aciduria contains excessive amounts of 3-methylglutaconic acid, 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:6085636	3-Hydroxy-3-methylglutaric acidura has been reported in 10  patients. This disorder is caused by a deficiency in activity of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid, and elevated amounts of 3-methylglutaric acid and 3-hydroxyisovaleric acid.;|In each urine sample there were very highly elevated amounts of 3-hydroxy-3-methylglutaric acid and 3-methylglutaconic acid.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:15505778	Urine excretion of 3-hydroxy-isovaleric acid, 3-methyl-glutaric acid, 3-methyl-glutaconic acid, and 3-hydroxy-3-methylglutaric acid were increased as determined by gas chromatography mass spectrometry (see Table). These metabolites were considered diagnostic of HMG CoA lyase deficiency.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:3063529	Each of the patients has excreted large amounts of 3-hydroxy-3-methylglutaric acid, 3-hydroxyisovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid in the urine;|The pattern of organic aciduria associated with HMG-CoA lyase deficiency is characteristic. It includes increased urinary excretion of 3-hydroxyisovaleric, 3-methylglutaric, 3-methylglutaconic and 3-hydroxy-3-methylglutaric acids.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:17692550	A preliminary diagnosis of HL deficiency may be indicated by the characteristic urinary organic acid profile, which includes high levels of 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:15164951	A preliminary diagnosis can be obtained from the characteristic urinary organic acid profiles, which include 3-hydroxy-3-methylglutaric acid, 3-hydroxy-isovaleric acid, 3-methylglutaconic acid and 3-methylglutaric acid.	best_biomarker_role;condition
AN6165-1	Increased C6DC acylcarnitine	C6DC acylcarnitine	PCCID:71296139	metabolite	3-Hydroxy-3-Methylglutaric Aciduria	OMIM:246450			diagnostic	plasma	UBERON:0001969		Pubmed:6489380	Urinary organic acid analysis, performed as described below, revealed metabolites suggestive of 3-hydroxy-3-methylglutaric aciduria.	best_biomarker_role;condition
AN6166-1	Increased 3-Hydroxyisovaleric acid	3-Hydroxyisovaleric acid	PCCID:69362	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:16010683	Patients  with  MCC  deficiency  show  elevated  urinary  excretion  of  3-hydroxyisovalerate   (3-HIVA)   and   3-methylcrotonylglycine   (3-MCG)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Hydroxyisovaleric acid	3-Hydroxyisovaleric acid	PCCID:69362	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:11131348	Patients with MCC deficiency show persistently high urinary excretion of 3-hydroxyisovalerate (3-HIVA) and 3-methylcrotonylglycine (3-MCG)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Hydroxyisovaleric acid	3-Hydroxyisovaleric acid	PCCID:69362	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:11181649	There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine,	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Hydroxyisovaleric acid	3-Hydroxyisovaleric acid	PCCID:69362	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:11170888	The metabolic phenotype characterizing MCC deficiency is the elevated excretion of the diagnostic compounds 3-methylcrotonylglycine or 3-hydroxyisovaleric acid	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Hydroxyisovaleric acid	3-Hydroxyisovaleric acid	PCCID:69362	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6166-1	Increased 3-Methylcrotonylglycine	3-Methylcrotonylglycine	PCCID:169485	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:16010683	Patients  with  MCC  deficiency  show  elevated  urinary  excretion  of  3-hydroxyisovalerate   (3-HIVA)   and   3-methylcrotonylglycine   (3-MCG)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Methylcrotonylglycine	3-Methylcrotonylglycine	PCCID:169485	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:11131348	Patients with MCC deficiency show persistently high urinary excretion of 3-hydroxyisovalerate (3-HIVA) and 3-methylcrotonylglycine (3-MCG)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Methylcrotonylglycine	3-Methylcrotonylglycine	PCCID:169485	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:11170888	The metabolic phenotype characterizing MCC deficiency is the elevated excretion of the diagnostic compounds 3-methylcrotonylglycine or 3-hydroxyisovaleric acid	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Methylcrotonylglycine	3-Methylcrotonylglycine	PCCID:169485	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:11181649	There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine,	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased 3-Methylcrotonylglycine	3-Methylcrotonylglycine	PCCID:169485	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6166-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	plasma	UBERON:0001969		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6166-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	plasma	UBERON:0001969		Pubmed:11181649	There is a characteristic organic aciduria with massive excretion of 3-hydroxyisovaleric acid and 3-methylcrotonylglycine,	best_biomarker_role;condition
AN6166-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	plasma	UBERON:0001969		Pubmed:16010683	Patients  with  MCC  deficiency  show  elevated  urinary  excretion  of  3-hydroxyisovalerate   (3-HIVA)   and   3-methylcrotonylglycine   (3-MCG)	best_biomarker_role;condition
AN6166-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	plasma	UBERON:0001969		Pubmed:11131348	Patients with MCC deficiency show persistently high urinary excretion of 3-hydroxyisovalerate (3-HIVA) and 3-methylcrotonylglycine (3-MCG)	best_biomarker_role;condition
AN6166-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-methylcrotonyl-CoA carboxylase deficiency	DOID:0050710			diagnostic	plasma	UBERON:0001969		Pubmed:11170888	The metabolic phenotype characterizing MCC deficiency is the elevated excretion of the diagnostic compounds 3-methylcrotonylglycine or 3-hydroxyisovaleric acid	best_biomarker_role;condition
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:7299555	Urinalysis demonstrated persistent moderate ketonuria on all determinations over this time period, and excretion of a-methyl acetoacetic acid, a-methyl-b-hydroxybutyric acid, and butanone was elevated.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:4143539	The major, unusual organic acids in the patients urine were a-methyl-b-hydroxybutyric acid and a-methylacetoacetate.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:30835345	Biochemical markers for beta-ketothiolase deficiency include high blood methylcrotonyl carnitine and urinary 2-methyl-3-hydroxybutyric acid.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Doi:10.1203/00006450-199402000-00076	Elevated 2-methyl-3-hydroxybutyric acid and triglyglycine excretion in urine are confirmed biomarkers for Ketothiolase deficiency.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:7173255	Elevated urinary tiglyglycine levels are found in patients with beta-ketothiolase deficiency.	best_biomarker_role;condition
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:7923765	Tiglyglycine is increased in the urine of patients with beta-ketothiolase deficiency and may serve as a diagnostic marker for disorders of the respiratory chain.	best_biomarker_role;condition
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:20157782	Concentrations were well beyond the cut-off values of tiglyl carnitine, 3-hydroxybutyrylcarnitine and 2-methyl-3-hydroxybutyrylcarnitine, 2-methyl-3-hydroxybutyric acid and tiglyl glycine.	best_biomarker_role;condition
AN6167-1	Increased 2-methyl-3-hydroxybutyric acid	2-methyl-3-hydroxybutyric acid	PCCID:160471	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:34001203	Almost all patients (23/25, 95%) exhibited elevated C5OH and C5:1 levels.;|Most patients exhibited typical blood acylcarnitine and urinary organic acid profiles. Interestingly, almost all patients (15/16, 94%) showed elevated 3-hydroxybutyrylcarnitine (C4OH) levels.	best_biomarker_role;condition
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:34001203	Almost all patients (23/25, 95%) exhibited elevated C5OH and C5:1 levels.;|Most patients exhibited typical blood acylcarnitine and urinary organic acid profiles. Interestingly, almost all patients (15/16, 94%) showed elevated 3-hydroxybutyrylcarnitine (C4OH) levels.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:20157782	Concentrations were well beyond the cut-off values of tiglyl carnitine, 3-hydroxybutyrylcarnitine and 2-methyl-3-hydroxybutyrylcarnitine, 2-methyl-3-hydroxybutyric acid and tiglyl glycine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:7173255	Elevated urinary tiglyglycine levels are found in patients with beta-ketothiolase deficiency.	best_biomarker_role;condition
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:7923765	Tiglyglycine is increased in the urine of patients with beta-ketothiolase deficiency and may serve as a diagnostic marker for disorders of the respiratory chain.	best_biomarker_role;condition
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:7299555	Urinalysis demonstrated persistent moderate ketonuria on all determinations over this time period, and excretion of a-methyl acetoacetic acid, a-methyl-b-hydroxybutyric acid, and butanone was elevated.	best_biomarker_role;condition
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:4143539	The major, unusual organic acids in the patients urine were a-methyl-b-hydroxybutyric acid and a-methylacetoacetate.	best_biomarker_role;condition
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:30835345	Biochemical markers for beta-ketothiolase deficiency include high blood methylcrotonyl carnitine and urinary 2-methyl-3-hydroxybutyric acid.	best_biomarker_role;condition
AN6167-1	Increased 3-hydroxybutyrylcarnitine	3-hydroxybutyrylcarnitine	PCCID:71464477	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Doi:10.1203/00006450-199402000-00076	Elevated 2-methyl-3-hydroxybutyric acid and triglyglycine excretion in urine are confirmed biomarkers for Ketothiolase deficiency.	best_biomarker_role;condition
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:34001203	Almost all patients (23/25, 95%) exhibited elevated C5OH and C5:1 levels.;|Most patients exhibited typical blood acylcarnitine and urinary organic acid profiles. Interestingly, almost all patients (15/16, 94%) showed elevated 3-hydroxybutyrylcarnitine (C4OH) levels.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:7173255	Elevated urinary tiglyglycine levels are found in patients with beta-ketothiolase deficiency.	best_biomarker_role;condition
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:7923765	Tiglyglycine is increased in the urine of patients with beta-ketothiolase deficiency and may serve as a diagnostic marker for disorders of the respiratory chain.	best_biomarker_role;condition
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:7299555	Urinalysis demonstrated persistent moderate ketonuria on all determinations over this time period, and excretion of a-methyl acetoacetic acid, a-methyl-b-hydroxybutyric acid, and butanone was elevated.	best_biomarker_role;condition
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:20157782	Concentrations were well beyond the cut-off values of tiglyl carnitine, 3-hydroxybutyrylcarnitine and 2-methyl-3-hydroxybutyrylcarnitine, 2-methyl-3-hydroxybutyric acid and tiglyl glycine.	best_biomarker_role;condition
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:4143539	The major, unusual organic acids in the patients urine were a-methyl-b-hydroxybutyric acid and a-methylacetoacetate.	best_biomarker_role;condition
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Pubmed:30835345	Biochemical markers for beta-ketothiolase deficiency include high blood methylcrotonyl carnitine and urinary 2-methyl-3-hydroxybutyric acid.	best_biomarker_role;condition
AN6167-1	Increased C5-OH acylcarnitine	C5-OH acylcarnitine	PCCID:71464474	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	plasma	UBERON:0001969		Doi:10.1203/00006450-199402000-00076	Elevated 2-methyl-3-hydroxybutyric acid and triglyglycine excretion in urine are confirmed biomarkers for Ketothiolase deficiency.	best_biomarker_role;condition
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:7923765	Tiglyglycine is increased in the urine of patients with beta-ketothiolase deficiency and may serve as a diagnostic marker for disorders of the respiratory chain.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:7173255	Elevated urinary tiglyglycine levels are found in patients with beta-ketothiolase deficiency.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Doi:10.1203/00006450-199402000-00076	Elevated 2-methyl-3-hydroxybutyric acid and triglyglycine excretion in urine are confirmed biomarkers for Ketothiolase deficiency.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:4143539	The major, unusual organic acids in the patients urine were a-methyl-b-hydroxybutyric acid and a-methylacetoacetate.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:18088573	Due to its increased concentration in blood, 3-hydroxyisovalerylcarnitine (C5OH-I) is an important indicator for the diagnosis of organic acidemias in newborns.	best_biomarker_role;condition
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:7299555	Urinalysis demonstrated persistent moderate ketonuria on all determinations over this time period, and excretion of a-methyl acetoacetic acid, a-methyl-b-hydroxybutyric acid, and butanone was elevated.	best_biomarker_role;condition
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:20157782	Concentrations were well beyond the cut-off values of tiglyl carnitine, 3-hydroxybutyrylcarnitine and 2-methyl-3-hydroxybutyrylcarnitine, 2-methyl-3-hydroxybutyric acid and tiglyl glycine.	best_biomarker_role;condition
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:34001203	Almost all patients (23/25, 95%) exhibited elevated C5OH and C5:1 levels.;|Most patients exhibited typical blood acylcarnitine and urinary organic acid profiles. Interestingly, almost all patients (15/16, 94%) showed elevated 3-hydroxybutyrylcarnitine (C4OH) levels.	best_biomarker_role;condition
AN6167-1	Increased tiglylglycine	Tiglylglycine	PCCID:6441567	metabolite	3-Ketothiolase Deficiency	OMIM:203750			diagnostic	urine	UBERON:0001088		Pubmed:30835345	Biochemical markers for beta-ketothiolase deficiency include high blood methylcrotonyl carnitine and urinary 2-methyl-3-hydroxybutyric acid.	best_biomarker_role;condition
AN6168-1	Increased 3-hydroxyglutaric acid	3-hydroxyglutaric acid	PCCID:181976	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:22728054	Plasma glutarylcarnitine and urinary 3-hydroxyglutaric acid were elevated in all patients	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased 3-hydroxyglutaric acid	3-hydroxyglutaric acid	PCCID:181976	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:16602100	Glutaric acidemia type 1 produces carnitine deficiency and increases levels of C5 dicarboxylic (glutaryl) carnitine in urine and plasma;|This disorder can be identified by increased glutaryl (C5DC) carnitine on newborn screening.;|With urine organic acid analysis, 3-OH-glutaric acid is the diagnostic metabolite	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased 3-hydroxyglutaric acid	3-hydroxyglutaric acid	PCCID:181976	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:31536184	GA-1 is suspected during the diagnostic evaluation of a newborn with an elevated concentration of 3-OH-GA in plasma or urine	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased 3-hydroxyglutaric acid	3-hydroxyglutaric acid	PCCID:181976	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:36221165	GCDH deficiency results in accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), glutaconic acid and glutarylcarnitine (C5DC) which can be detected in body fluids (urine, plasma, cerebrospinal fluid [CSF])	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased 3-hydroxyglutaric acid	3-hydroxyglutaric acid	PCCID:181976	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:25256449	Urine organic acid analysis usually shows increased levels of glutaric acid (GA), 3-hydroxyglutaric acid (3OHGA), glutaryl-CoA, glutarylcarnitine, and glutaconic acids, although glutaric acid and dicarboxylic carnitines can be completely normal in some patients.	best_biomarker_role;condition
AN6168-1	Increased 3-hydroxyglutaric acid	3-hydroxyglutaric acid	PCCID:181976	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:8552212	The biochemical picture is characterized by the large amounts of glutaric, 3-hydroxyglutaric and glutaconic acids in the urine.	best_biomarker_role;condition
AN6168-1	Increased 3-hydroxyglutaric acid	3-hydroxyglutaric acid	PCCID:181976	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:21431622	This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines).	best_biomarker_role;condition
AN6168-1	Increased glutaric acid	Glutaric acid	PCCID:743	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:25256449	Urine organic acid analysis usually shows increased levels of glutaric acid (GA), 3-hydroxyglutaric acid (3OHGA), glutaryl-CoA, glutarylcarnitine, and glutaconic acids, although glutaric acid and dicarboxylic carnitines can be completely normal in some patients.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased glutaric acid	Glutaric acid	PCCID:743	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:8552212	The biochemical picture is characterized by the large amounts of glutaric, 3-hydroxyglutaric and glutaconic acids in the urine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased glutaric acid	Glutaric acid	PCCID:743	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:21431622	This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines).	best_biomarker_role;condition
AN6168-1	Increased glutaric acid	Glutaric acid	PCCID:743	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:31536184	GA-1 is suspected during the diagnostic evaluation of a newborn with an elevated concentration of 3-OH-GA in plasma or urine	best_biomarker_role;condition
AN6168-1	Increased glutaric acid	Glutaric acid	PCCID:743	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:36221165	GCDH deficiency results in accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), glutaconic acid and glutarylcarnitine (C5DC) which can be detected in body fluids (urine, plasma, cerebrospinal fluid [CSF])	best_biomarker_role;condition
AN6168-1	Increased glutaric acid	Glutaric acid	PCCID:743	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:16602100	Glutaric acidemia type 1 produces carnitine deficiency and increases levels of C5 dicarboxylic (glutaryl) carnitine in urine and plasma;|This disorder can be identified by increased glutaryl (C5DC) carnitine on newborn screening.;|With urine organic acid analysis, 3-OH-glutaric acid is the diagnostic metabolite	best_biomarker_role;condition
AN6168-1	Increased glutaric acid	Glutaric acid	PCCID:743	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	urine	UBERON:0001088		Pubmed:22728054	Plasma glutarylcarnitine and urinary 3-hydroxyglutaric acid were elevated in all patients	best_biomarker_role;condition
AN6168-1	Increased glutarylcarnitine	Glutaryl (C5DC) carnitine	PCCID:71317118	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	plasma	UBERON:0001969		Pubmed:22728054	Plasma glutarylcarnitine and urinary 3-hydroxyglutaric acid were elevated in all patients	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased glutarylcarnitine	Glutaryl (C5DC) carnitine	PCCID:71317118	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	plasma	UBERON:0001969		Pubmed:16602100	Glutaric acidemia type 1 produces carnitine deficiency and increases levels of C5 dicarboxylic (glutaryl) carnitine in urine and plasma;|This disorder can be identified by increased glutaryl (C5DC) carnitine on newborn screening.;|With urine organic acid analysis, 3-OH-glutaric acid is the diagnostic metabolite	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased glutarylcarnitine	Glutaryl (C5DC) carnitine	PCCID:71317118	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	plasma	UBERON:0001969		Pubmed:21431622	This defect gives rise to elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine which can be detected by gas chromatography/mass spectrometry (organic acids) or tandem mass spectrometry (acylcarnitines).	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6168-1	Increased glutarylcarnitine	Glutaryl (C5DC) carnitine	PCCID:71317118	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	plasma	UBERON:0001969		Pubmed:31536184	GA-1 is suspected during the diagnostic evaluation of a newborn with an elevated concentration of 3-OH-GA in plasma or urine	best_biomarker_role;condition
AN6168-1	Increased glutarylcarnitine	Glutaryl (C5DC) carnitine	PCCID:71317118	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	plasma	UBERON:0001969		Pubmed:36221165	GCDH deficiency results in accumulation of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA), glutaconic acid and glutarylcarnitine (C5DC) which can be detected in body fluids (urine, plasma, cerebrospinal fluid [CSF])	best_biomarker_role;condition
AN6168-1	Increased glutarylcarnitine	Glutaryl (C5DC) carnitine	PCCID:71317118	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	plasma	UBERON:0001969		Pubmed:8552212	The biochemical picture is characterized by the large amounts of glutaric, 3-hydroxyglutaric and glutaconic acids in the urine.	best_biomarker_role;condition
AN6168-1	Increased glutarylcarnitine	Glutaryl (C5DC) carnitine	PCCID:71317118	metabolite	Glutaric acidemia type 1	OMIM:231670			diagnostic	plasma	UBERON:0001969		Pubmed:25256449	Urine organic acid analysis usually shows increased levels of glutaric acid (GA), 3-hydroxyglutaric acid (3OHGA), glutaryl-CoA, glutarylcarnitine, and glutaconic acids, although glutaric acid and dicarboxylic carnitines can be completely normal in some patients.	best_biomarker_role;condition
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	plasma	UBERON:0001969		Pubmed:16602101	isovalerylcarnitine and isovalerylglycine are the hallmarks of this disorder in plasma and urine, respectively, and are elevated regardless of a patients metabolic condition.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	plasma	UBERON:0001969		Pubmed:22004070	The pathognomonic metabolite, isovalerylglycine, can be detected on urine organic acid analysis;|isovalerylcarnitine can be detected in dried blood spots or plasma on tandem mass spectrometry	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	plasma	UBERON:0001969		Pubmed:6549017	Gas chromatography/mass spectrometry have unequivocally identified the existence of isovalerylcarnitine (IVC), a new metabolite specific for this disorder.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	plasma	UBERON:0001969		Pubmed:33072933	In urine, the elevation of IVG confirms the metabolic diagnosis of IVA;|Isovaleryl (C5)-carnitine is the marker metabolite used for newborn screening in Isovaleric Acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	plasma	UBERON:0001969		Pubmed:1777996	In this study, we determined the levels of both IVG and IVC in amniotic fluids obtained at 32 gestational weeks by FAB-MS/MS, and demonstrated that this technique is a practical and accurate method for the prenatal diagnosis of isovaleric acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	plasma	UBERON:0001969		Pubmed:7659686	The diagnosis can be established biochemically by the demonstration of increased levels of isovalerylglycine (IVG) and 3-hydroxyisovaleric acid in urine	best_biomarker_role;condition
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:16602101	isovalerylcarnitine and isovalerylglycine are the hallmarks of this disorder in plasma and urine, respectively, and are elevated regardless of a patients metabolic condition.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:22004070	The pathognomonic metabolite, isovalerylglycine, can be detected on urine organic acid analysis;|isovalerylcarnitine can be detected in dried blood spots or plasma on tandem mass spectrometry	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:6549017	Gas chromatography/mass spectrometry have unequivocally identified the existence of isovalerylcarnitine (IVC), a new metabolite specific for this disorder.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:33072933	In urine, the elevation of IVG confirms the metabolic diagnosis of IVA;|Isovaleryl (C5)-carnitine is the marker metabolite used for newborn screening in Isovaleric Acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:1777996	In this study, we determined the levels of both IVG and IVC in amniotic fluids obtained at 32 gestational weeks by FAB-MS/MS, and demonstrated that this technique is a practical and accurate method for the prenatal diagnosis of isovaleric acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylcarnitine	Isovalerylcarnitine	PCCID:169235	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:7659686	The diagnosis can be established biochemically by the demonstration of increased levels of isovalerylglycine (IVG) and 3-hydroxyisovaleric acid in urine	best_biomarker_role;condition
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	urine	UBERON:0001088		Pubmed:16602101	isovalerylcarnitine and isovalerylglycine are the hallmarks of this disorder in plasma and urine, respectively, and are elevated regardless of a patients metabolic condition.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	urine	UBERON:0001088		Pubmed:7659686	The diagnosis can be established biochemically by the demonstration of increased levels of isovalerylglycine (IVG) and 3-hydroxyisovaleric acid in urine	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	urine	UBERON:0001088		Pubmed:33072933	In urine, the elevation of IVG confirms the metabolic diagnosis of IVA;|Isovaleryl (C5)-carnitine is the marker metabolite used for newborn screening in Isovaleric Acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	urine	UBERON:0001088		Pubmed:22004070	The pathognomonic metabolite, isovalerylglycine, can be detected on urine organic acid analysis;|isovalerylcarnitine can be detected in dried blood spots or plasma on tandem mass spectrometry	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	urine	UBERON:0001088		Pubmed:1777996	In this study, we determined the levels of both IVG and IVC in amniotic fluids obtained at 32 gestational weeks by FAB-MS/MS, and demonstrated that this technique is a practical and accurate method for the prenatal diagnosis of isovaleric acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	urine	UBERON:0001088		Pubmed:6549017	Gas chromatography/mass spectrometry have unequivocally identified the existence of isovalerylcarnitine (IVC), a new metabolite specific for this disorder.	best_biomarker_role;condition
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:16602101	isovalerylcarnitine and isovalerylglycine are the hallmarks of this disorder in plasma and urine, respectively, and are elevated regardless of a patients metabolic condition.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:7659686	The diagnosis can be established biochemically by the demonstration of increased levels of isovalerylglycine (IVG) and 3-hydroxyisovaleric acid in urine	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:33072933	In urine, the elevation of IVG confirms the metabolic diagnosis of IVA;|Isovaleryl (C5)-carnitine is the marker metabolite used for newborn screening in Isovaleric Acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:22004070	The pathognomonic metabolite, isovalerylglycine, can be detected on urine organic acid analysis;|isovalerylcarnitine can be detected in dried blood spots or plasma on tandem mass spectrometry	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:1777996	In this study, we determined the levels of both IVG and IVC in amniotic fluids obtained at 32 gestational weeks by FAB-MS/MS, and demonstrated that this technique is a practical and accurate method for the prenatal diagnosis of isovaleric acidemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6169-1	Increased Isovalerylglycine	Isovalerylglycine	PCCID:546304	metabolite	isovaleric acidemia	DOID:14753			diagnostic	amniotic fluid	UBERON:0000173		Pubmed:6549017	Gas chromatography/mass spectrometry have unequivocally identified the existence of isovalerylcarnitine (IVC), a new metabolite specific for this disorder.	best_biomarker_role;condition
AN6170-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia  (Cobalamin disorders)	OMIM:251110			diagnostic	plasma	UBERON:0001969		Pubmed:35038174	Methylmalonic acid, another primary metabolite, is a potential biomarker, but only in patients with MMA.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6170-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia  (Cobalamin disorders)	OMIM:251110			diagnostic	plasma	UBERON:0001969		Pubmed:28070528	A definitive diagnosis of the disorder is based on urine organic acid analysis using gas chromatography/mass spectrometry (GC/MS). Organic acids can be measured using any body fluid, but urine is the most efficient for determining the type of disorder. The determination of organic acids and glycine conjugates in urine is key for the diagnosis and follow-up of MMA.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6170-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia  (Cobalamin disorders)	OMIM:251110			diagnostic	plasma	UBERON:0001969		Pubmed:36582607	methylmalonic acid excretion significantly increased in cblC-MMA patients	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6170-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia  (Cobalamin disorders)	OMIM:251110			diagnostic	urine	UBERON:0001088		Pubmed:35038174	Methylmalonic acid, another primary metabolite, is a potential biomarker, but only in patients with MMA.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6170-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia  (Cobalamin disorders)	OMIM:251110			diagnostic	urine	UBERON:0001088		Pubmed:28070528	A definitive diagnosis of the disorder is based on urine organic acid analysis using gas chromatography/mass spectrometry (GC/MS). Organic acids can be measured using any body fluid, but urine is the most efficient for determining the type of disorder. The determination of organic acids and glycine conjugates in urine is key for the diagnosis and follow-up of MMA.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6170-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia  (Cobalamin disorders)	OMIM:251110			diagnostic	urine	UBERON:0001088		Pubmed:36582607	methylmalonic acid excretion significantly increased in cblC-MMA patients	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased  2-Methylcitric acid	2-Methylcitric acid	PCCID:439681	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:37243446	Elevated  plasma  concentration  of  propionylcarnitine(C3) form the basis of newborn screening for MMA.;|This makes them attractive candidates for drug development targeting both disorders andsimultaneous  determination  of  2-methylcitric  acid (2MCA), 3-OH propionic acid, have been proposed as bio-markers for diagnostic and monitoring purposes inboth disorders of propionyl-CoA metabolism.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased  2-Methylcitric acid	2-Methylcitric acid	PCCID:439681	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:25750861	The best way to accomplish the diagnosis is to study urinary nonvolatile organic acid patterns by using gas chromatography mass spectrometry. MMA level in urine was measured by GCMS	best_biomarker_role;condition
AN6171-1	Increased  2-Methylcitric acid	2-Methylcitric acid	PCCID:439681	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:30712249	In all of 25 patients, the diagnosis of MMA was confirmed, due to significantly elevated methylmalonic acid levels and methylcitric acids in the urine.	best_biomarker_role;condition
AN6171-1	Increased  2-Methylcitric acid	2-Methylcitric acid	PCCID:439681	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:26454439	The median urine level of methylmalonate was 598.96 (18.50-2976.25) mmol/mol creatinine	best_biomarker_role;condition
AN6171-1	Increased  2-Methylcitric acid	2-Methylcitric acid	PCCID:439681	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:31622506	The patients in our group were typically diagnosed based on clinical symptoms and biochemical examinations, including elevated blood propionylcarnitine and urinary methylmalonic acid levels.	best_biomarker_role;condition
AN6171-1	Increased 3-OH Propionic acid	3-OH Propionic acid	PCCID:68152	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:37243446	Elevated  plasma  concentration  of  propionylcarnitine(C3) form the basis of newborn screening for MMA.;|This makes them attractive candidates for drug development targeting both disorders andsimultaneous  determination  of  2-methylcitric  acid (2MCA), 3-OH propionic acid, have been proposed as bio-markers for diagnostic and monitoring purposes inboth disorders of propionyl-CoA metabolism.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased 3-OH Propionic acid	3-OH Propionic acid	PCCID:68152	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:25750861	The best way to accomplish the diagnosis is to study urinary nonvolatile organic acid patterns by using gas chromatography mass spectrometry. MMA level in urine was measured by GCMS	best_biomarker_role;condition
AN6171-1	Increased 3-OH Propionic acid	3-OH Propionic acid	PCCID:68152	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:30712249	In all of 25 patients, the diagnosis of MMA was confirmed, due to significantly elevated methylmalonic acid levels and methylcitric acids in the urine.	best_biomarker_role;condition
AN6171-1	Increased 3-OH Propionic acid	3-OH Propionic acid	PCCID:68152	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:26454439	The median urine level of methylmalonate was 598.96 (18.50-2976.25) mmol/mol creatinine	best_biomarker_role;condition
AN6171-1	Increased 3-OH Propionic acid	3-OH Propionic acid	PCCID:68152	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:31622506	The patients in our group were typically diagnosed based on clinical symptoms and biochemical examinations, including elevated blood propionylcarnitine and urinary methylmalonic acid levels.	best_biomarker_role;condition
AN6171-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	urine	UBERON:0001088		Pubmed:25750861	The best way to accomplish the diagnosis is to study urinary nonvolatile organic acid patterns by using gas chromatography mass spectrometry. MMA level in urine was measured by GCMS	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	urine	UBERON:0001088		Pubmed:26454439	The median urine level of methylmalonate was 598.96 (18.50-2976.25) mmol/mol creatinine	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	urine	UBERON:0001088		Pubmed:31622506	The patients in our group were typically diagnosed based on clinical symptoms and biochemical examinations, including elevated blood propionylcarnitine and urinary methylmalonic acid levels.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	urine	UBERON:0001088		Pubmed:30712249	In all of 25 patients, the diagnosis of MMA was confirmed, due to significantly elevated methylmalonic acid levels and methylcitric acids in the urine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased Methylmalonic Acid	Methylmalonic Acid	PCCID:487	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	urine	UBERON:0001088		Pubmed:37243446	Elevated  plasma  concentration  of  propionylcarnitine(C3) form the basis of newborn screening for MMA.;|This makes them attractive candidates for drug development targeting both disorders andsimultaneous  determination  of  2-methylcitric  acid (2MCA), 3-OH propionic acid, have been proposed as bio-markers for diagnostic and monitoring purposes inboth disorders of propionyl-CoA metabolism.	best_biomarker_role;condition
AN6171-1	Increased Propionylcarnitine (C3)	Propionylcarnitine (C3)	PCCID:107738	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:37243446	Elevated  plasma  concentration  of  propionylcarnitine(C3) form the basis of newborn screening for MMA.;|This makes them attractive candidates for drug development targeting both disorders andsimultaneous  determination  of  2-methylcitric  acid (2MCA), 3-OH propionic acid, have been proposed as bio-markers for diagnostic and monitoring purposes inboth disorders of propionyl-CoA metabolism.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6171-1	Increased Propionylcarnitine (C3)	Propionylcarnitine (C3)	PCCID:107738	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:25750861	The best way to accomplish the diagnosis is to study urinary nonvolatile organic acid patterns by using gas chromatography mass spectrometry. MMA level in urine was measured by GCMS	best_biomarker_role;condition
AN6171-1	Increased Propionylcarnitine (C3)	Propionylcarnitine (C3)	PCCID:107738	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:30712249	In all of 25 patients, the diagnosis of MMA was confirmed, due to significantly elevated methylmalonic acid levels and methylcitric acids in the urine.	best_biomarker_role;condition
AN6171-1	Increased Propionylcarnitine (C3)	Propionylcarnitine (C3)	PCCID:107738	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:26454439	The median urine level of methylmalonate was 598.96 (18.50-2976.25) mmol/mol creatinine	best_biomarker_role;condition
AN6171-1	Increased Propionylcarnitine (C3)	Propionylcarnitine (C3)	PCCID:107738	metabolite	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	OMIM:251000			monitoring	plasma	UBERON:0001969		Pubmed:31622506	The patients in our group were typically diagnosed based on clinical symptoms and biochemical examinations, including elevated blood propionylcarnitine and urinary methylmalonic acid levels.	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:33595124	sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, can be optimised by 2-methylcitrate.;|sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, obtained during the first days of life, can be optimised by measuring C3/C2 ratio,	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:27216769	By including 2-methylcitric acid in the screening algorithm, the positive predictive value of our primary and secondary screening targets improved from 8.7 to 64.3%.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:30217751	Quantification of methylcitrate provides important diagnostic clues for propionic acidemia	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:31451751	This is the first report to describe the potential role of MCA and MCA/CA in dried blood spots as diagnostic and monitoring biomarkers for inherited disorders of propionyl-CoA metabolism.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:27900673	C3 is not sensitive or specific, the diagnostic sensitivity is improved using acylcarnitine ratios (increased ratio of C3 to C2).	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:32681732	Primary metabolites include propionyl-carnitine (C3), methylcitric acid (MCA), 3-hydroxypropionic acid;|Significant differences between the two diseases were found for the C3/C2 ratio.	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:35038174	Elevated 3-hydroxypropionic acid in urine, combined with the presence of 2-MCA in urine, is diagnostic of PA;|In an affected newborn, acetylcarnitine (C2) is usually normal, and thus the C3/C2 ratio (a proxy for propionyl-CoA/acetyl-CoA) can be elevated up to 20-fold	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	2-methylcitrate	PCCID:439681	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:17510301	Our methodology is capable of monitoring and quantifying MMA and 3OH-PA during newborn screening as a 2nd-tier test. It can follow up on and diagnose PA and methylmalonic acidurias.	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:35038174	Elevated 3-hydroxypropionic acid in urine, combined with the presence of 2-MCA in urine, is diagnostic of PA;|In an affected newborn, acetylcarnitine (C2) is usually normal, and thus the C3/C2 ratio (a proxy for propionyl-CoA/acetyl-CoA) can be elevated up to 20-fold	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:32681732	Primary metabolites include propionyl-carnitine (C3), methylcitric acid (MCA), 3-hydroxypropionic acid;|Significant differences between the two diseases were found for the C3/C2 ratio.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:17510301	Our methodology is capable of monitoring and quantifying MMA and 3OH-PA during newborn screening as a 2nd-tier test. It can follow up on and diagnose PA and methylmalonic acidurias.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:33595124	sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, can be optimised by 2-methylcitrate.;|sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, obtained during the first days of life, can be optimised by measuring C3/C2 ratio,	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:27216769	By including 2-methylcitric acid in the screening algorithm, the positive predictive value of our primary and secondary screening targets improved from 8.7 to 64.3%.	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:27900673	C3 is not sensitive or specific, the diagnostic sensitivity is improved using acylcarnitine ratios (increased ratio of C3 to C2).	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:30217751	Quantification of methylcitrate provides important diagnostic clues for propionic acidemia	best_biomarker_role;condition
AN6172-1	Increased 2-methylcitrate	3-hydroxypropionate	PCCID:5459847	metabolite	propionic acidemia	DOID:14701			diagnostic	urine	UBERON:0001088		Pubmed:31451751	This is the first report to describe the potential role of MCA and MCA/CA in dried blood spots as diagnostic and monitoring biomarkers for inherited disorders of propionyl-CoA metabolism.	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:33595124	sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, can be optimised by 2-methylcitrate.;|sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, obtained during the first days of life, can be optimised by measuring C3/C2 ratio,	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:35038174	Elevated 3-hydroxypropionic acid in urine, combined with the presence of 2-MCA in urine, is diagnostic of PA;|In an affected newborn, acetylcarnitine (C2) is usually normal, and thus the C3/C2 ratio (a proxy for propionyl-CoA/acetyl-CoA) can be elevated up to 20-fold	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:32681732	Primary metabolites include propionyl-carnitine (C3), methylcitric acid (MCA), 3-hydroxypropionic acid;|Significant differences between the two diseases were found for the C3/C2 ratio.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:27900673	C3 is not sensitive or specific, the diagnostic sensitivity is improved using acylcarnitine ratios (increased ratio of C3 to C2).	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:31451751	This is the first report to describe the potential role of MCA and MCA/CA in dried blood spots as diagnostic and monitoring biomarkers for inherited disorders of propionyl-CoA metabolism.	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:27216769	By including 2-methylcitric acid in the screening algorithm, the positive predictive value of our primary and secondary screening targets improved from 8.7 to 64.3%.	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:30217751	Quantification of methylcitrate provides important diagnostic clues for propionic acidemia	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C2 acylcarnitine	PCCID:7045767	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:17510301	Our methodology is capable of monitoring and quantifying MMA and 3OH-PA during newborn screening as a 2nd-tier test. It can follow up on and diagnose PA and methylmalonic acidurias.	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:33595124	sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, can be optimised by 2-methylcitrate.;|sensitivity and specificity for diagnosis of MMA and PA from dried blood spots, obtained during the first days of life, can be optimised by measuring C3/C2 ratio,	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:35038174	Elevated 3-hydroxypropionic acid in urine, combined with the presence of 2-MCA in urine, is diagnostic of PA;|In an affected newborn, acetylcarnitine (C2) is usually normal, and thus the C3/C2 ratio (a proxy for propionyl-CoA/acetyl-CoA) can be elevated up to 20-fold	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:32681732	Primary metabolites include propionyl-carnitine (C3), methylcitric acid (MCA), 3-hydroxypropionic acid;|Significant differences between the two diseases were found for the C3/C2 ratio.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:27900673	C3 is not sensitive or specific, the diagnostic sensitivity is improved using acylcarnitine ratios (increased ratio of C3 to C2).	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:31451751	This is the first report to describe the potential role of MCA and MCA/CA in dried blood spots as diagnostic and monitoring biomarkers for inherited disorders of propionyl-CoA metabolism.	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:27216769	By including 2-methylcitric acid in the screening algorithm, the positive predictive value of our primary and secondary screening targets improved from 8.7 to 64.3%.	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:30217751	Quantification of methylcitrate provides important diagnostic clues for propionic acidemia	best_biomarker_role;condition
AN6172-1	Increased C3/C2 acylcarnitine ratio	C3 acylcarnitine	PCCID:107738	metabolite	propionic acidemia	DOID:14701			diagnostic	blood	UBERON:0000178		Pubmed:17510301	Our methodology is capable of monitoring and quantifying MMA and 3OH-PA during newborn screening as a 2nd-tier test. It can follow up on and diagnose PA and methylmalonic acidurias.	best_biomarker_role;condition
AN6173-1	Increased Hydroxyacylcarnitine (C18:1-OH)	Hydroxyacylcarnitine (C18:1-OH)	PCCID:71464503	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:30029694	elevated concentartions of C18:1-OH (0.46 _mol/l; cut-off <_0.04 _mol/l);|elevated concentrations of C16-OH (1.62 _mol/l; cut-off <_0.05 _mol/l)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6173-1	Increased Hydroxyacylcarnitine (C18:1-OH)	Hydroxyacylcarnitine (C18:1-OH)	PCCID:71464503	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:34768374	Elevations in C14:1 and C16:1 acylcarnitines, and C16-OH and C18:1-OH hydroxyacylcarnitines, have been observed	best_biomarker_role;condition
AN6173-1	Increased hydroxypalmitoylcarnitine (C16-OH)	Hydroxyacylcarnitine (C18:1-OH)	PCCID:71464503	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:34768374	Elevations in C14:1 and C16:1 acylcarnitines, and C16-OH and C18:1-OH hydroxyacylcarnitines, have been observed	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6173-1	Increased hydroxypalmitoylcarnitine (C16-OH)	Hydroxyacylcarnitine (C18:1-OH)	PCCID:71464503	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:30029694	elevated concentartions of C18:1-OH (0.46 _mol/l; cut-off <_0.04 _mol/l);|elevated concentrations of C16-OH (1.62 _mol/l; cut-off <_0.05 _mol/l)	best_biomarker_role;condition
AN6173-1	Increased hydroxypalmitoylcarnitine (C16-OH)	Hydroxypalmitoylcarnitine (C16-OH)	PCCID:126456228	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:30029694	elevated concentartions of C18:1-OH (0.46 _mol/l; cut-off <_0.04 _mol/l);|elevated concentrations of C16-OH (1.62 _mol/l; cut-off <_0.05 _mol/l)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6173-1	Increased hydroxypalmitoylcarnitine (C16-OH)	Hydroxypalmitoylcarnitine (C16-OH)	PCCID:126456228	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:34768374	Elevations in C14:1 and C16:1 acylcarnitines, and C16-OH and C18:1-OH hydroxyacylcarnitines, have been observed	best_biomarker_role;condition
AN6173-1	Increased Hydroxyacylcarnitine (C18:1-OH)	Hydroxypalmitoylcarnitine (C16-OH)	PCCID:126456228	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:34768374	Elevations in C14:1 and C16:1 acylcarnitines, and C16-OH and C18:1-OH hydroxyacylcarnitines, have been observed	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6173-1	Increased Hydroxyacylcarnitine (C18:1-OH)	Hydroxypalmitoylcarnitine (C16-OH)	PCCID:126456228	metabolite	very long chain acyl-CoA dehydrogenase deficiency	DOID:0080155			diagnostic	plasma	UBERON:0001969		Pubmed:30029694	elevated concentartions of C18:1-OH (0.46 _mol/l; cut-off <_0.04 _mol/l);|elevated concentrations of C16-OH (1.62 _mol/l; cut-off <_0.05 _mol/l)	best_biomarker_role;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	csf	UBERON:0001359		Pubmed:7682674	Elevated concentrations of argininosuccinic acid and its anhydrides in cerebrospinal fluid, pseudouridine, and uridine, and elevated concentrations of uracil and orotic acid in urine are biomarkers for argininosuccinic aciduria.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	csf	UBERON:0001359		Pubmed:21329179	In patients with argininosuccinic aciduria, the plasma citrulline is usually elevated to levels of 150 to 250 _mol/L.;|The diagnosis was confirmed by detection of excessive levels of argininosuccinate in the urine and/or plasma.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	csf	UBERON:0001359		Pubmed:7164925	Argininosuccinic aciduria is detected by over-excretion of argininosuccinic acid and negligible enzyme activity in erythrocyte lysates.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	csf	UBERON:0001359		Pubmed:5365174	Accumulation of ASA and, in some cases, of its immediate precursor citrulline occurs in the blood, the cerebrospinal fluid and especially in the urine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	csf	UBERON:0001359		Pubmed:652408	Argininosuccinic aciduria is autosomal recessive and has a reduced enzyme activity, with elevated plasma citrulline and glutamine levels,	best_biomarker_role;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	csf	UBERON:0001359		Pubmed:32931185	Citrulline is the most significant marker to detect argininosuccinic aciduria, with a concentration of 22 _ mol/L in healthy infants and 220 mol/L in infants suffering from the disorder.	best_biomarker_role;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:7682674	Elevated concentrations of argininosuccinic acid and its anhydrides in cerebrospinal fluid, pseudouridine, and uridine, and elevated concentrations of uracil and orotic acid in urine are biomarkers for argininosuccinic aciduria.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:21329179	In patients with argininosuccinic aciduria, the plasma citrulline is usually elevated to levels of 150 to 250 _mol/L.;|The diagnosis was confirmed by detection of excessive levels of argininosuccinate in the urine and/or plasma.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:7164925	Argininosuccinic aciduria is detected by over-excretion of argininosuccinic acid and negligible enzyme activity in erythrocyte lysates.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:5365174	Accumulation of ASA and, in some cases, of its immediate precursor citrulline occurs in the blood, the cerebrospinal fluid and especially in the urine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:652408	Argininosuccinic aciduria is autosomal recessive and has a reduced enzyme activity, with elevated plasma citrulline and glutamine levels,	best_biomarker_role;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:32931185	Citrulline is the most significant marker to detect argininosuccinic aciduria, with a concentration of 22 _ mol/L in healthy infants and 220 mol/L in infants suffering from the disorder.	best_biomarker_role;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	urine	UBERON:0001088		Pubmed:7682674	Elevated concentrations of argininosuccinic acid and its anhydrides in cerebrospinal fluid, pseudouridine, and uridine, and elevated concentrations of uracil and orotic acid in urine are biomarkers for argininosuccinic aciduria.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	urine	UBERON:0001088		Pubmed:21329179	In patients with argininosuccinic aciduria, the plasma citrulline is usually elevated to levels of 150 to 250 _mol/L.;|The diagnosis was confirmed by detection of excessive levels of argininosuccinate in the urine and/or plasma.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	urine	UBERON:0001088		Pubmed:7164925	Argininosuccinic aciduria is detected by over-excretion of argininosuccinic acid and negligible enzyme activity in erythrocyte lysates.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	urine	UBERON:0001088		Pubmed:5365174	Accumulation of ASA and, in some cases, of its immediate precursor citrulline occurs in the blood, the cerebrospinal fluid and especially in the urine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	urine	UBERON:0001088		Pubmed:652408	Argininosuccinic aciduria is autosomal recessive and has a reduced enzyme activity, with elevated plasma citrulline and glutamine levels,	best_biomarker_role;condition
AN6174-1	Increased argininosuccinic acid	Argininosuccinic acid	PCCID:16950	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	urine	UBERON:0001088		Pubmed:32931185	Citrulline is the most significant marker to detect argininosuccinic aciduria, with a concentration of 22 _ mol/L in healthy infants and 220 mol/L in infants suffering from the disorder.	best_biomarker_role;condition
AN6174-1	Increased Citrulline	Citrulline	PCCID:9750	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:5365174	Accumulation of ASA and, in some cases, of its immediate precursor citrulline occurs in the blood, the cerebrospinal fluid and especially in the urine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased Citrulline	Citrulline	PCCID:9750	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:652408	Argininosuccinic aciduria is autosomal recessive and has a reduced enzyme activity, with elevated plasma citrulline and glutamine levels,	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased Citrulline	Citrulline	PCCID:9750	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:21329179	In patients with argininosuccinic aciduria, the plasma citrulline is usually elevated to levels of 150 to 250 _mol/L.;|The diagnosis was confirmed by detection of excessive levels of argininosuccinate in the urine and/or plasma.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased Citrulline	Citrulline	PCCID:9750	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:32931185	Citrulline is the most significant marker to detect argininosuccinic aciduria, with a concentration of 22 _ mol/L in healthy infants and 220 mol/L in infants suffering from the disorder.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6174-1	Increased Citrulline	Citrulline	PCCID:9750	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:7682674	Elevated concentrations of argininosuccinic acid and its anhydrides in cerebrospinal fluid, pseudouridine, and uridine, and elevated concentrations of uracil and orotic acid in urine are biomarkers for argininosuccinic aciduria.	best_biomarker_role;condition
AN6174-1	Increased Citrulline	Citrulline	PCCID:9750	metabolite	argininosuccinic aciduria	DOID:14755			diagnostic	plasma	UBERON:0001969		Pubmed:7164925	Argininosuccinic aciduria is detected by over-excretion of argininosuccinic acid and negligible enzyme activity in erythrocyte lysates.	best_biomarker_role;condition
AN6175-1	Increased Phenylacetic acid	Phenylacetic acid	PCCID:999	metabolite	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:26410738	The largest value of AUC (0.987) with high specificity (0.936) and sensitivity (1.000) was obtained by the ROC curve of phenylacetic acid at its cutoff value (17.244 mmol/mol creatinine)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6175-1	Increased Phenylacetic acid	Phenylacetic acid	PCCID:999	metabolite	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:12101068	The enzyme defect leads to a specific pattern of plasma amino acids with increased Phe at normal or decreased Tyr	best_biomarker_role;condition
AN6175-1	Increased Phenylacetic acid	Phenylacetic acid	PCCID:999	metabolite	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:31608347	Although plasma Phe is commonly used for treatment monitoring of PKU patients, urine offers a non-invasive biofluid better suited for routine assessment of several disease-related signatures of aberrant Phe catabolism caused by poor dietary protein restriction, as well as nutritional inadequacy notably prevalent among older PKU patients.	best_biomarker_role;condition
AN6175-1	Increased Phenylacetic acid	Phenylacetic acid	PCCID:999	metabolite	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:17591452	Blood phenylalanine (Phe) levels provide a practical and reliable method for the diagnosis and monitoring of metabolic status in patients with phenylketonuria (PKU)	best_biomarker_role;condition
AN6175-1	Increased Phenylacetic acid	Phenylacetic acid	PCCID:999	metabolite	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:12401368	The present method for the quantitative analysis of Phe and Tyr in neonatal blood sample is simple, rapid and sensitive, which makes it suitable for simultaneous screening for PKU and tyrosinemia.	best_biomarker_role;condition
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	plasma	UBERON:0001969		Pubmed:17591452	Blood phenylalanine (Phe) levels provide a practical and reliable method for the diagnosis and monitoring of metabolic status in patients with phenylketonuria (PKU)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	plasma	UBERON:0001969		Pubmed:12101068	The enzyme defect leads to a specific pattern of plasma amino acids with increased Phe at normal or decreased Tyr	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	plasma	UBERON:0001969		Pubmed:12401368	The present method for the quantitative analysis of Phe and Tyr in neonatal blood sample is simple, rapid and sensitive, which makes it suitable for simultaneous screening for PKU and tyrosinemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	plasma	UBERON:0001969		Pubmed:31608347	Although plasma Phe is commonly used for treatment monitoring of PKU patients, urine offers a non-invasive biofluid better suited for routine assessment of several disease-related signatures of aberrant Phe catabolism caused by poor dietary protein restriction, as well as nutritional inadequacy notably prevalent among older PKU patients.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	plasma	UBERON:0001969		Pubmed:26410738	The largest value of AUC (0.987) with high specificity (0.936) and sensitivity (1.000) was obtained by the ROC curve of phenylacetic acid at its cutoff value (17.244 mmol/mol creatinine)	best_biomarker_role;condition
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:17591452	Blood phenylalanine (Phe) levels provide a practical and reliable method for the diagnosis and monitoring of metabolic status in patients with phenylketonuria (PKU)	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:12101068	The enzyme defect leads to a specific pattern of plasma amino acids with increased Phe at normal or decreased Tyr	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:12401368	The present method for the quantitative analysis of Phe and Tyr in neonatal blood sample is simple, rapid and sensitive, which makes it suitable for simultaneous screening for PKU and tyrosinemia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:31608347	Although plasma Phe is commonly used for treatment monitoring of PKU patients, urine offers a non-invasive biofluid better suited for routine assessment of several disease-related signatures of aberrant Phe catabolism caused by poor dietary protein restriction, as well as nutritional inadequacy notably prevalent among older PKU patients.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6175-1	Increased phenylalanine	Phenylalanine	PCCID:6140	amino acid	phenylketonuria	DOID:9281			diagnostic	urine	UBERON:0001088		Pubmed:26410738	The largest value of AUC (0.987) with high specificity (0.936) and sensitivity (1.000) was obtained by the ROC curve of phenylacetic acid at its cutoff value (17.244 mmol/mol creatinine)	best_biomarker_role;condition
AN6176-1	Increased homocysteine	Homocysteine	PCCID:91552	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:20142522	Screening for this disorder is typically, hyperhomocysteinemia, hypermethioninemia, and hypocysteinemia, and the urinary excretion of methionine, homocysteine, and its oxidized form (homocystine) is elevated.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased homocysteine	Homocysteine	PCCID:91552	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:29279830	Metabolic screening revealed elevated concentrations of serum homocysteine and methionine and a normal serum concentration of vitamin B12.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased homocysteine	Homocysteine	PCCID:91552	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:10075100	There was a very abnormal plasma amino-acid pattern with severe hyperhomocysteinemia and hypermethioninemia, suggestive of classical homocystinuria.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased homocysteine	Homocysteine	PCCID:91552	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:5948395	Homocystinuria was diagnosed in a newborn infant by detection of homocystine in urine on the fourth day of life, and by the demonstration of a marked elevation of serum methionine concentration on the fifth day	best_biomarker_role;condition
AN6176-1	Increased methionine	Methionine	PCCID:6137	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:5948395	Homocystinuria was diagnosed in a newborn infant by detection of homocystine in urine on the fourth day of life, and by the demonstration of a marked elevation of serum methionine concentration on the fifth day	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased methionine	Methionine	PCCID:6137	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:10075100	There was a very abnormal plasma amino-acid pattern with severe hyperhomocysteinemia and hypermethioninemia, suggestive of classical homocystinuria.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased methionine	Methionine	PCCID:6137	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:29279830	Metabolic screening revealed elevated concentrations of serum homocysteine and methionine and a normal serum concentration of vitamin B12.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased methionine	Methionine	PCCID:6137	amino acid	homocystinuria	DOID:9263			diagnostic	serum	UBERON:0001977		Pubmed:20142522	Screening for this disorder is typically, hyperhomocysteinemia, hypermethioninemia, and hypocysteinemia, and the urinary excretion of methionine, homocysteine, and its oxidized form (homocystine) is elevated.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased homocysteine	Total homocysteine	PCCID:91552	metabolite	homocystinuria	DOID:9263			diagnostic	urine	UBERON:0001088		Pubmed:5948395	Homocystinuria was diagnosed in a newborn infant by detection of homocystine in urine on the fourth day of life, and by the demonstration of a marked elevation of serum methionine concentration on the fifth day	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6176-1	Increased homocysteine	Total homocysteine	PCCID:91552	metabolite	homocystinuria	DOID:9263			diagnostic	urine	UBERON:0001088		Pubmed:20142522	Screening for this disorder is typically, hyperhomocysteinemia, hypermethioninemia, and hypocysteinemia, and the urinary excretion of methionine, homocysteine, and its oxidized form (homocystine) is elevated.	best_biomarker_role;condition
AN6176-1	Increased homocysteine	Total homocysteine	PCCID:91552	metabolite	homocystinuria	DOID:9263			diagnostic	urine	UBERON:0001088		Pubmed:29279830	Metabolic screening revealed elevated concentrations of serum homocysteine and methionine and a normal serum concentration of vitamin B12.	best_biomarker_role;condition
AN6176-1	Increased homocysteine	Total homocysteine	PCCID:91552	metabolite	homocystinuria	DOID:9263			diagnostic	urine	UBERON:0001088		Pubmed:10075100	There was a very abnormal plasma amino-acid pattern with severe hyperhomocysteinemia and hypermethioninemia, suggestive of classical homocystinuria.	best_biomarker_role;condition
AN6177-1	Increased alloisoleucine	Alloisoleucine	PCCID:99288	metabolite	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Pubmed:28919799	Maple syrup urine disease (MSUD) is an inborn error of metabolism resulting in the production of the pathognomonic disease marker, alloisoleucine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6177-1	Increased alloisoleucine	Alloisoleucine	PCCID:99288	metabolite	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Pubmed:10508118	The present findings indicate that plasma L-alloisoleucine above the cutoff value of 5 mmol/L is the most specific and most sensitive diagnostic marker for all forms of MSUD.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6177-1	Increased alloisoleucine	Alloisoleucine	PCCID:99288	metabolite	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Pubmed:18178665	Newborn screening for maple syrup urine disease (MSUD) relies on finding increased concentrations of the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine by tandem mass spectrometry (MS/MS).;|d-Alloisoleucine (allo-Ile) is the only pathognomonic marker of MSUD	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6177-1	Increased alloisoleucine	Alloisoleucine	PCCID:99288	metabolite	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Doi:10.3390/ijns2020002	A sensitive and rapid second-tier UPLC-MS/MS method to determine branched-chain amino acids from the initial extraction of the screening sample and markedly reduces the false-positive rate and the associated anxiety and costs	best_biomarker_role;condition
AN6177-1	Increased branched chain amino acids	Branched chain amino acids	PCCID:9886134	amino acid	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Pubmed:18178665	Newborn screening for maple syrup urine disease (MSUD) relies on finding increased concentrations of the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine by tandem mass spectrometry (MS/MS).;|d-Alloisoleucine (allo-Ile) is the only pathognomonic marker of MSUD	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6177-1	Increased branched chain amino acids	Branched chain amino acids	PCCID:9886134	amino acid	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Pubmed:28919799	Maple syrup urine disease (MSUD) is an inborn error of metabolism resulting in the production of the pathognomonic disease marker, alloisoleucine.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6177-1	Increased branched chain amino acids	Branched chain amino acids	PCCID:9886134	amino acid	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Doi:10.3390/ijns2020002	A sensitive and rapid second-tier UPLC-MS/MS method to determine branched-chain amino acids from the initial extraction of the screening sample and markedly reduces the false-positive rate and the associated anxiety and costs	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6177-1	Increased branched chain amino acids	Branched chain amino acids	PCCID:9886134	amino acid	maple syrup urine disease	DOID:9269			diagnostic	serum	UBERON:0001977		Pubmed:10508118	The present findings indicate that plasma L-alloisoleucine above the cutoff value of 5 mmol/L is the most specific and most sensitive diagnostic marker for all forms of MSUD.	best_biomarker_role;condition
AN6178-1	Increased succinylacetone	Succinylacetone	PCCID:5312	metabolite	tyrosinemia type I	DOID:0050726			diagnostic	blood	UBERON:0000178		Pubmed:25066104	Succinylacetone (SUAC) is a pathognomonic marker of tyrosinemia type I and its detection by newborn screening programs improves its specificity.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6178-1	Increased succinylacetone	Succinylacetone	PCCID:5312	metabolite	tyrosinemia type I	DOID:0050726			diagnostic	blood	UBERON:0000178		Pubmed:23430836	Succinylacetone (SUAC) accumulation in blood and urine is a primary marker for tyrosinemia type I.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6178-1	Increased succinylacetone	Succinylacetone	PCCID:5312	metabolite	tyrosinemia type I	DOID:0050726			diagnostic	blood	UBERON:0000178		Pubmed:15498530	The reference range in the control group of unaffected newborn was determined to be <2 micromol/L, while SA in retrieved DBS from HT patients was significantly elevated, measuring 46.7, 36.5, and 23.2 micromol/L.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6178-1	Increased succinylacetone	Succinylacetone	PCCID:5312	metabolite	tyrosinemia type I	DOID:0050726			diagnostic	blood	UBERON:0000178		Pubmed:28274233	Sensitivity (29 cases in total) and specificity (34,403 controls in total) were 100% in the case control studies. Screening for Tyrosinemia type 1 using tandem mass spectrometry measurement of succinylacetone from dried blood spots appears to be promising.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 17-Hydroxyprogesterone	17-Hydroxyprogesterone	PCCID:6238	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:16551734	17-hydroxyprogesterone and 21-deoxycortisol levels are elevated in patients with congenital adrenal hyperplasia, suggesting their potential use as markers for diagnosis and monitoring.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 17-Hydroxyprogesterone	17-Hydroxyprogesterone	PCCID:6238	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:6609026	17-hydroxyprogesterone and 11-deoxycortisol are specific markers for congenital adrenal hyperplasia due to deficiencies of 21- and 11-hydroxylase activities, respectively.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 17-Hydroxyprogesterone	17-Hydroxyprogesterone	PCCID:6238	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:4372245	17-hydroxyprogesterone and 21-deoxycortisol levels are elevated in untreated congenital adrenal hyperplasia patients.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 17-Hydroxyprogesterone	17-Hydroxyprogesterone	PCCID:6238	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:29264476	An LC-MS/MS serum steroid profile, including 17-hydroxy-progesterone and 21-deoxycortisol, provides a reliable etiologic diagnosis of congenital adrenal hyperplasia.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 17-Hydroxyprogesterone	17-Hydroxyprogesterone	PCCID:6238	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:31450227	Time to Replace 17OHP with 21-Deoxycortisol as the analyte of choice for 21OHD	best_biomarker_role;condition
AN6179-1	Increased 17-Hydroxyprogesterone	17-Hydroxyprogesterone	PCCID:6238	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:34780778	21deoxycortisol is a key disease marker of 21OHD and can be used to improve the accuracy of newborn screening for this disorder.	best_biomarker_role;condition
AN6179-1	Increased 17-Hydroxyprogesterone	17-Hydroxyprogesterone	PCCID:6238	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:33117906	Recent studies have noted the utility of 21-deoxycortisol, in addition to 17OHP, as a diagnostic marker for 21OHD	best_biomarker_role;condition
AN6179-1	Increased 21-Deoxycortisol	21-Deoxycortisol	PCCID:92827	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:16551734	17-hydroxyprogesterone and 21-deoxycortisol levels are elevated in patients with congenital adrenal hyperplasia, suggesting their potential use as markers for diagnosis and monitoring.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 21-Deoxycortisol	21-Deoxycortisol	PCCID:92827	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:31450227	Time to Replace 17OHP with 21-Deoxycortisol as the analyte of choice for 21OHD	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 21-Deoxycortisol	21-Deoxycortisol	PCCID:92827	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:34780778	21deoxycortisol is a key disease marker of 21OHD and can be used to improve the accuracy of newborn screening for this disorder.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 21-Deoxycortisol	21-Deoxycortisol	PCCID:92827	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:33117906	Recent studies have noted the utility of 21-deoxycortisol, in addition to 17OHP, as a diagnostic marker for 21OHD	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6179-1	Increased 21-Deoxycortisol	21-Deoxycortisol	PCCID:92827	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:29264476	An LC-MS/MS serum steroid profile, including 17-hydroxy-progesterone and 21-deoxycortisol, provides a reliable etiologic diagnosis of congenital adrenal hyperplasia.	best_biomarker_role;condition
AN6179-1	Increased 21-Deoxycortisol	21-Deoxycortisol	PCCID:92827	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:4372245	17-hydroxyprogesterone and 21-deoxycortisol levels are elevated in untreated congenital adrenal hyperplasia patients.	best_biomarker_role;condition
AN6179-1	Increased 21-Deoxycortisol	21-Deoxycortisol	PCCID:92827	metabolite	congenital adrenal hyperplasia	DOID:0050811			diagnostic	blood	UBERON:0000178		Pubmed:6609026	17-hydroxyprogesterone and 11-deoxycortisol are specific markers for congenital adrenal hyperplasia due to deficiencies of 21- and 11-hydroxylase activities, respectively.	best_biomarker_role;condition
AN6180-1	Increased thyroid stimulating harmone	Thyroid stimulating hormone	PCSID:485716527	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:10447022	Other screening programs, for example in Japan, use a primary TSH test; some programs in the United States and Canada are switching to this screening strategy to screen central hypothyroidism.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6180-1	Increased thyroid stimulating harmone	Thyroid stimulating hormone	PCSID:485716527	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:37326450	Primary CH is characterized by low blood TH and elevated thyroid-stimulating hormone (TSH) concentrations.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6180-1	Increased thyroid stimulating harmone	Thyroid stimulating hormone	PCSID:485716527	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:17220056	Blood spot T4 or TSH or both can be used in neonatal screening for CH. The latter, which is more sensitive, is not cost effective, so the first two are used in different programs in the world. TSH screening was shown to be more specific in the diagnosis of CH.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6180-1	Increased thyroid stimulating harmone	Thyroid stimulating hormone	PCSID:485716527	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:20537182	The diagnosis should be confirmed by finding an elevated serum TSH and low T4 or free T4 level.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6180-1	Decreased thyroxine	Thyroxine hormone	PCCID:5819	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:10447022	Other screening programs, for example in Japan, use a primary TSH test; some programs in the United States and Canada are switching to this screening strategy to screen central hypothyroidism.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6180-1	Decreased thyroxine	Thyroxine hormone	PCCID:5819	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:37326450	Primary CH is characterized by low blood TH and elevated thyroid-stimulating hormone (TSH) concentrations.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6180-1	Decreased thyroxine	Thyroxine hormone	PCCID:5819	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:17220056	Blood spot T4 or TSH or both can be used in neonatal screening for CH. The latter, which is more sensitive, is not cost effective, so the first two are used in different programs in the world. TSH screening was shown to be more specific in the diagnosis of CH.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6180-1	Decreased thyroxine	Thyroxine hormone	PCCID:5819	protein	congenital hypothyroidism	DOID:0050328			diagnostic	blood	UBERON:0000178		Pubmed:20537182	The diagnosis should be confirmed by finding an elevated serum TSH and low T4 or free T4 level.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6181-1	Biotinidase activity	Biotinidase	PCSID:379981166	protein	biotinidase deficiency	DOID:856			diagnostic	blood	UBERON:0000178		Pubmed:3944695	A simple colorimetric screening procedure can detect biotinidase deficiency in newborns,with excellent sensitivity and specificity.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6181-1	Biotinidase activity	Biotinidase	PCSID:379981166	protein	biotinidase deficiency	DOID:856			diagnostic	blood	UBERON:0000178		Pubmed:6848914	Biotinidase activity was determined colorimetrically by measuring the liberation of p-aminobenzoate from biotin-p-aminobenzoate, an artificial substrate of biotinidase.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6181-1	Biotinidase activity	Biotinidase	PCSID:379981166	protein	biotinidase deficiency	DOID:856			diagnostic	blood	UBERON:0000178		Pubmed:15060693	Confirmation of biotinidase activity in serum was obtained for babies suspected of having the deficiency and for their parents by a quantitative colorimetric assay using biotinyl-p-aminobenzoate as described previously	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6181-1	Biotinidase activity	Biotinidase	PCSID:379981166	protein	biotinidase deficiency	DOID:856			diagnostic	blood	UBERON:0000178		Pubmed:6661819	Biotinidase activity in serum from normal individuals is comparable to that determined by the colorimetric assay, but the radioassay is approximately 100 times more sensitive.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6182-1	Increased sweat chloride	Sweat chloride	PCCID:312	electrolyte	cystic fibrosis	DOID:1485			diagnostic	sweat	UBERON:0001089		Pubmed:24660233	Sweat chloride is useful in multicenter trials as a biomarker of CFTR activity and to test the effect of CFTR potentiators.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6182-1	Increased sweat chloride	Sweat chloride	PCCID:312	electrolyte	cystic fibrosis	DOID:1485			diagnostic	sweat	UBERON:0001089		Pubmed:18823769	Early determination of cystic fibrosis by electrochemical chloride quantification in sweat.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6182-1	Increased sweat chloride	Sweat chloride	PCCID:312	electrolyte	cystic fibrosis	DOID:1485			diagnostic	sweat	UBERON:0001089		Pubmed:18728376	Standardized sweat chloride test can be a useful diagnostic tool for cystic fibrosis in Koreans, with all confirmed cases showing sweat chloride levels above 60 mmol/L.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6182-1	Increased sweat chloride	Sweat chloride	PCCID:312	electrolyte	cystic fibrosis	DOID:1485			diagnostic	sweat	UBERON:0001089		Pubmed:28576637	In screening positive babies, the diagnosis of CF must be confirmed by a sweat test demonstrating a sweat chloride concentration above 60mmol/L.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6183-1	Increased Glc4	Glc4	PCCID:5793	oligosaccharide	glycogen storage disease II	DOID:2752			diagnostic	urine	UBERON:0001088		Pubmed:15886040	Glc4, has been shown to be a putative biomarker for the diagnosis of Pompe disease.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6183-1	Increased Glc4	Glc4	PCCID:5793	oligosaccharide	glycogen storage disease II	DOID:2752			diagnostic	urine	UBERON:0001088		Pubmed:22252961	Urinary Glc4 had high sensitivity (95%) and specificity (84%) as a diagnostic biomarker within this at-risk group and is a highly predictive biomarker of Pompe disease in infantile patients.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6183-1	Increased Glc4	Glc4	PCCID:5793	oligosaccharide	glycogen storage disease II	DOID:2752			diagnostic	urine	UBERON:0001088		Doi:10.1016/j.mgene.2018.05.064.	A comparison with the until now best biomarkers for Pompe (Hex4 and Glc4 in urine) will be presented.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6183-1	Increased Glc4	Glc4	PCCID:5793	oligosaccharide	glycogen storage disease II	DOID:2752			diagnostic	urine	UBERON:0001088		Pubmed:23756115	Glc4 urinary levels are found to be high in patients suffering from Pompe disease	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6183-1	Increased Glc4	Glc4	PCCID:5793	oligosaccharide	glycogen storage disease II	DOID:2752			diagnostic	urine	UBERON:0001088		Doi:10.1007/s11696-018-0623-3	increased levels of specific glucose tetrasaccharide _Glc(1___6)_Glc(1___4)_Glc(1___4)Glc (Glc4), which was approved as a non-invasive biomarker of glycogen accumulation in the muscles of Pompe patients.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6183-1	Increased Glc4	Glc4	PCCID:5793	oligosaccharide	glycogen storage disease II	DOID:2752			diagnostic	urine	UBERON:0001088		Pubmed:32069240	urinary excretion of the tetrasaccharide 6-_-D-glucopyranosyl-maltotriose (Glc4) has been proposed as a marker for the diagnosis and monitoring of Pompe disease (PD).	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6184-1	Decreased Creatine	Creatine	PCCID:586	metabolite	guanidinoacetate methyltransferase deficiency	DOID:0050799			diagnostic	csf	UBERON:0001359		Pubmed:18652076	GAA is the main intermediary product in creatine biosynthesis. In GAMT deficiency, GAA accumulates about 200-fold in CSF.;|The biochemical hallmarks of these disorders include cerebral creatine deficiency and specific disturbances in metabolites of creatine metabolism in body fluids	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6184-1	Decreased Creatine	Creatine	PCCID:586	metabolite	guanidinoacetate methyltransferase deficiency	DOID:0050799			diagnostic	csf	UBERON:0001359		Pubmed:15234333	Creatine in serum was in the low normal range, and creatine excretion during 24 h was decreased;|GAA concentrations in plasma, urine, and CSF were markedly elevated	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6184-1	Decreased Creatine	Creatine	PCCID:586	metabolite	guanidinoacetate methyltransferase deficiency	DOID:0050799			diagnostic	csf	UBERON:0001359		Pubmed:34440375	The biochemical signature of GAMT-D is the increase in guanidinoacetic acid (GAA) concentration associated with low levels of creatine in bodily fluids (urine, plasma, and cerebrospinal fluid (CSF))	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6184-1	Increased guanidinoacetic acid	Guanidinoacetic acid	PCCID:763	metabolite	guanidinoacetate methyltransferase deficiency	DOID:0050799			diagnostic	csf	UBERON:0001359		Pubmed:18652076	GAA is the main intermediary product in creatine biosynthesis. In GAMT deficiency, GAA accumulates about 200-fold in CSF.;|The biochemical hallmarks of these disorders include cerebral creatine deficiency and specific disturbances in metabolites of creatine metabolism in body fluids	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6184-1	Increased guanidinoacetic acid	Guanidinoacetic acid	PCCID:763	metabolite	guanidinoacetate methyltransferase deficiency	DOID:0050799			diagnostic	csf	UBERON:0001359		Pubmed:15234333	Creatine in serum was in the low normal range, and creatine excretion during 24 h was decreased;|GAA concentrations in plasma, urine, and CSF were markedly elevated	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6184-1	Increased guanidinoacetic acid	Guanidinoacetic acid	PCCID:763	metabolite	guanidinoacetate methyltransferase deficiency	DOID:0050799			diagnostic	csf	UBERON:0001359		Pubmed:34440375	The biochemical signature of GAMT-D is the increase in guanidinoacetic acid (GAA) concentration associated with low levels of creatine in bodily fluids (urine, plasma, and cerebrospinal fluid (CSF))	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6185-1	Decreased Alpha-L-iduronidase activity	Alpha-L-iduronidase	PCSID:381121448	protein	mucopolysaccharidosis I	DOID:12802			diagnostic	blood	UBERON:0000178		Pubmed:32154058	Bivariate analysis of iduronidase enzyme activity with HS in newborn DBS can accurately predict early MPSI symptoms, control false positive rates, and enhance presymptomatic treatment.;|To improve the accuracy of presymptomatic prediction for MPSI, we propose an NBS tool based on known biomarkers, alpha-L-iduronidase enzyme activity (IDUA) and level of the glycosaminoglycan (GAG) heparan sulfate (HS). Bivariate analysis of IDUA with HS in newborn DBS can accurately predict early MPSI symptoms, control false positive rates, and enhance presymptomatic treatment.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6185-1	Decreased Alpha-L-iduronidase activity	Alpha-L-iduronidase	PCSID:381121448	protein	mucopolysaccharidosis I	DOID:12802			diagnostic	blood	UBERON:0000178		Pubmed:30057281	MPS I is an autosomal, recessive disorder, caused by a deficiency of hydrolase _-L-iduronidase.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6185-1	Decreased Alpha-L-iduronidase activity	Alpha-L-iduronidase	PCSID:381121448	protein	mucopolysaccharidosis I	DOID:12802			diagnostic	blood	UBERON:0000178		Pubmed:23958290	Mucopolysaccharidoses I caused by deficiency of Alpha-L-iduronidase enzyme, which leads to accumulation of Heparan and Dermatan sulfates.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6186-1	Decreased iduronate-2-sulfatase activity	Iduronate-2-sulfatase	PCSID:481101668	protein	mucopolysaccharidosis II	DOID:12799			diagnostic	blood	UBERON:0000178		Pubmed:15797184	Mucopolysaccharidosis type II (Hunter disease, iduronate-2-sulfatase deficiency) was diagnosed by demonstrating low iduronate-2-sulfatase activity.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6186-1	Decreased iduronate-2-sulfatase activity	Iduronate-2-sulfatase	PCSID:481101668	protein	mucopolysaccharidosis II	DOID:12799			diagnostic	blood	UBERON:0000178		Pubmed:18245410	Absent or low iduronate-2-sulfatase activity in males is diagnostic of MPS II	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6186-1	Decreased iduronate-2-sulfatase activity	Iduronate-2-sulfatase	PCSID:481101668	protein	mucopolysaccharidosis II	DOID:12799			diagnostic	blood	UBERON:0000178		Pubmed:30057281	MPS II is caused by the deficiency of hydrolase Iduronate-2-sulfatase.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6186-1	Decreased iduronate-2-sulfatase activity	Iduronate-2-sulfatase	PCSID:481101668	protein	mucopolysaccharidosis II	DOID:12799			diagnostic	blood	UBERON:0000178		Pubmed:8281149	Iduronate-2-sulfatase gene mutations in patients with mucopolysaccharidosis type II allow for fast and reliable carrier detection and prenatal diagnosis.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6186-1	Decreased iduronate-2-sulfatase activity	Iduronate-2-sulfatase	PCSID:481101668	protein	mucopolysaccharidosis II	DOID:12799			diagnostic	blood	UBERON:0000178		Pubmed:7581397	Mutations in the iduronate-2-sulfatase gene are associated with severe reductions in iduronate-2-sulfatase enzyme activity in patients with Mucopolysaccharidosis type II.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6187-1	Increased very long chain fatty acids	Very long chain fatty acids	PCSID:405235122	lipid	adrenoleukodystrophy	DOID:10588			diagnostic	blood	UBERON:0000178		Pubmed:15670720	Enhanced VLCFA elongation is associated with impaired peroxisomal beta-oxidation in X-linked adrenoleukodystrophy, suggesting its potential use as a reliable biomarker.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6187-1	Increased very long chain fatty acids	Very long chain fatty acids	PCSID:405235122	lipid	adrenoleukodystrophy	DOID:10588			diagnostic	blood	UBERON:0000178		Pubmed:11748843	In males, unambiguous diagnosis of X-linked adrenoleukodystrophy can be achieved by demonstrating elevated levels of VLCFA in plasma.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6187-1	Increased very long chain fatty acids	Very long chain fatty acids	PCSID:405235122	lipid	adrenoleukodystrophy	DOID:10588			diagnostic	blood	UBERON:0000178		Pubmed:15924749	ABCD1 gene mutational analysis and postnatal plasma VLCFAs level test verified that amniocytes VLCFAs level analysis is a reliable prenatal diagnostic method for this disease.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6187-1	Increased very long chain fatty acids	Very long chain fatty acids	PCSID:405235122	lipid	adrenoleukodystrophy	DOID:10588			diagnostic	blood	UBERON:0000178		Pubmed:32934269	Serum VLCFA are reliable biomarkers for detecting X-linked Adrenoleukodystrophy with a sensitivity of 97% and specificity of 94.1%.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
AN6187-1	Increased very long chain fatty acids	Very long chain fatty acids	PCSID:405235122	lipid	adrenoleukodystrophy	DOID:10588			diagnostic	blood	UBERON:0000178		Doi:10.47895/amp.v51i3.1963	VLCFA analysis has a significant diagnostic yield of 54% for X-linked adrenoleukodystrophy, making it a reliable biomarker.	assessed_biomarker_entity;best_biomarker_role;biomarker;condition;specimen
